index	sentence	Gene	Mutation
0	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Leu19Phe
1	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Lys117Asn
2	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Ala146Thr
3	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	Arg164Gln
4	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Lys117Asn
5	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Ala146Thr
6	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Leu19Phe
7	Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras	K-Ras	Arg164Gln
8	Ras proteins regulate signal transduction by activating a number of downstream effector proteins, including the cytoplasmic serine/threonine protein kinase B-Raf (Figure 1)	 protein kinase B-Raf	serine/threonine
9	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	T to A
10	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	valine to glutamic acid
11	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	V600E
12	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	T to A
13	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	valine to glutamic acid
14	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	V600E
15	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12V
16	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12D
17	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G13D
18	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	Q61H
19	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	L19F
20	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	K117N
21	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	A146T
22	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	R164Q
23	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12V
24	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G12D
25	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	G13D
26	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	Q61H
27	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	L19F
28	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	K117N
29	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	A146T
30	Site-directed mutagenesis (SDM) was carried out on the pEFHA wt K-Ras plasmid using the QuikChange II SDM kit (Agilent, South Queensferry, Edinburgh, UK) according to the manufacturer's instructions to generate the following K-Ras mutations: G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q, using the oligonucleotide primers described in Table 1.	K-Ras	R164Q
31	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12V
32	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12D
33	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G13D
34	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	Q61H
35	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	L19F
36	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	K117N
37	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	A146T
38	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	R164Q
39	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12V
40	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G12D
41	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	G13D
42	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	Q61H
43	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	L19F
44	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	K117N
45	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	A146T
46	NIH3T3 cells were seeded at 2.5 x 105 cells in 35 mm culture dishes and allowed to adhere overnight before transfection with 250 ng of either pEF.6, pEFHA (wt K-Ras) or plasmids containing one of the following K-Ras mutants: G12V, G12D, G13D, Q61H, L19F, K117N, A146T or R164Q	K-Ras	R164Q
47	500 mug of cell lysate from each sample was incubated with 10 mug of Raf-1 RBD agarose at 4 C for 30 min with gentle rocking	Raf-1	C for 30
48	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
49	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
50	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12C
51	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
52	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
53	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
54	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
55	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
56	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
57	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
58	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
59	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12C
60	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
61	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
62	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
63	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
64	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
65	NIH3T3 cells were plated at 2.5 x 105 cells per well in a 6-well plate and, following overnight attachment, transfected with 250 ng of pEF, wt K-Ras or one of the K-Ras mutants: G12V, G12D, G12C, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
66	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	C for 5
67	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	C for 5
68	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	G57T
69	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	Leu19Phe
70	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	V600E
71	Together, these K-Ras mutations and the B-Raf V600E mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%	K-Ras	V600E
72	Together, these K-Ras mutations and the B-Raf V600E mutation increase overall Ras pathway mutation frequency from 27.4 to 37.8%	B-Raf	V600E
73	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
74	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
75	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
76	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
77	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
78	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
79	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
80	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
81	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
82	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
83	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
84	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
85	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
86	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
87	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
88	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
89	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12V
90	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G12D
91	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	G13D
92	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	Q61H
93	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	L19F
94	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	K117N
95	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	A146T
96	To compare the transformation potential of the K-Ras mutants, therefore, NIH3T3 cells were transiently transfected with plasmids expressing wt K-Ras and the K-Ras mutations G12V, G12D, G13D, Q61H, L19F, K117N, A146T and R164Q	K-Ras	R164Q
97	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	G12V
98	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	L19F
99	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	K117N
100	Figure 4 illustrates the results of our analysis where, consistent with our focus formation experiments, the K-Ras G12V and L19F, K117N and A146T mutations are clearly in the active GTP-bound conformation	K-Ras	A146T
101	In contrast, the R164Q mutation, like wt K-Ras, was not GTP-bound.	K-Ras	R164Q
102	It is interesting to note that the codon 12 mutants were most similar to wt K-Ras, whereas the K117N and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants	K-Ras	K117N
103	It is interesting to note that the codon 12 mutants were most similar to wt K-Ras, whereas the K117N and A146T mutants clustered with the activating codon 13 and codon 61 hotspot mutants	K-Ras	A146T
104	The presence of R164Q in cluster 2, rather than in cluster 1 with wt K-Ras was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.	K-Ras	R164Q
105	The presence of R164Q in cluster 2, rather than in cluster 1 with wt K-Ras was therefore initially surprising, but suggests that the R164Q mutation also has an 'activating' phenotype, albeit attenuated relative to the other mutations studied.	K-Ras	R164Q
106	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of R164Q	Ptpre	R164Q
107	However, there were examples of genes that were induced by all of the mutants studied, including the protein tyrosine phosphatase Ptpre and the Rho GTPase activating protein Arhgap6, and multiple examples of genes induced or repressed by all of the mutants with the exception of R164Q	Arhgap6	R164Q
108	RFLP analysis of B-Raf V599E mutation	Raf	V599E
109	The B-Raf V599E mutation was detected using a novel RFLP assay, where the presence of the mutation destroyed a recognition site for the restriction enzyme TspRI	Raf	V599E
110	Samples without the B-Raf V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp	B-Raf	V599E
111	Samples without the B-Raf V599E mutation were digested to produce bands of 124, 78 and 22 bp, whereas samples homozygous for the V599E mutation produced bands of 202 and 22 bp	B-Raf	V599E
112	Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation	HRAS	p.Lys117Arg
113	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	L19F
114	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	K117N
115	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	A146T
116	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	R164Q
117	(B) The transforming potential of L19F, K117N, A146T and R164Q mutations were compared with the hotspot mutation G12V and wt K-Ras	K-Ras	G12V
118	The K-Ras G12V construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.	K-Ras	G12V
119	The K-Ras G12V construct was included as a positive control for K-Ras protein in the active GTP-bound conformation.	K-Ras	G12V
120	The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation	Aurora2	serine/threonine
121	The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation	AIK	serine/threonine
122	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA1/2	rs299290
123	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	HMMR	rs299290
124	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA1	rs299290
125	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA2	rs299290
126	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA1	rs299290
127	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	Cox	rs299290
128	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of breast cancer risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)	BRCA2	rs299290
129	Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.	HMMR	rs299290
130	Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.	BRCA1	rs299290
131	Effect of HMMR rs299290 variation on breast cancer risk among BRCA1 and BRCA2 mutation carriers.	BRCA2	rs299290
132	Forrest plots show HRs and 95% CIs of the additive model (rs299290 C allele) for all participating centers ordered by sample size (n>30) of BRCA1 mutation carriers (left panel, wHR per study center are shown in Table S2; right panel, effect on BRCA2 mutation carriers)	BRCA1	rs299290
133	Forrest plots show HRs and 95% CIs of the additive model (rs299290 C allele) for all participating centers ordered by sample size (n>30) of BRCA1 mutation carriers (left panel, wHR per study center are shown in Table S2; right panel, effect on BRCA2 mutation carriers)	BRCA2	rs299290
134	Analysis of public gene expression datasets suggests that the rs299290 risk allele is associated with HMMR germline over-expression (see also Table S3)	HMMR	rs299290
135	Since rs299284 is at the fourth base position of HMMR exon 5, we evaluated the potential alteration of the splicing pattern of this exon or the ratio of the alternative exon 4	HMMR	rs299284
136	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)	ER	rs299290
137	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)	BRCA1	rs299290
138	In data provided by several CIMBA groups (Text S1), no ER-positive tumors were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)	BRCA2	rs299290
139	That is, despite the expected differences in the frequency of tumor types between the two sets of carriers, heterogeneity was observed in the distribution of rs299290 genotypes in BRCA1, but not BRCA2, mutation carriers	BRCA1	rs299290
140	That is, despite the expected differences in the frequency of tumor types between the two sets of carriers, heterogeneity was observed in the distribution of rs299290 genotypes in BRCA1, but not BRCA2, mutation carriers	BRCA2	rs299290
141	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	BRCA1	S7
142	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	RHAMM	S7
143	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	RHAMM	S7
144	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in breast cancer cell lines derived from BRCA1 mutation carriers	BRCA1	S7
145	BRCA1 depletion, however, did not alter AURKA levels (Figure S7)	BRCA1	S7
146	BRCA1 depletion, however, did not alter AURKA levels (Figure S7)	AURKA	S7
147	In contrast to single depletions, simultaneous reduction of AURKA and RHAMM levels recovered normal acini formation (Figure 4C-G), possibly implying a negative regulatory relationship between RHAMM abundance and AURKA activity	AURKA	4C-G
148	In contrast to single depletions, simultaneous reduction of AURKA and RHAMM levels recovered normal acini formation (Figure 4C-G), possibly implying a negative regulatory relationship between RHAMM abundance and AURKA activity	RHAMM	4C-G
149	In contrast to single depletions, simultaneous reduction of AURKA and RHAMM levels recovered normal acini formation (Figure 4C-G), possibly implying a negative regulatory relationship between RHAMM abundance and AURKA activity	RHAMM	4C-G
150	In contrast to single depletions, simultaneous reduction of AURKA and RHAMM levels recovered normal acini formation (Figure 4C-G), possibly implying a negative regulatory relationship between RHAMM abundance and AURKA activity	AURKA	4C-G
151	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure S7C)	AURKA	S7C
152	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure S7C)	RHAMM	S7C
153	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure S7C)	AURKA	S7C
154	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure S7C)	BRCA1	S7C
155	Consistently, AURKA depletion reduced RHAMM levels (Figure S7C), while simultaneous depletion of AURKA and BRCA1 recovered RHAMM to control levels (Figure S7C)	RHAMM	S7C
156	In MCF10A cells, AURKA abundance and activity determined total RHAMM as well as pT703-RHAMM levels (Figure S10A)	AURKA	S10A
157	In MCF10A cells, AURKA abundance and activity determined total RHAMM as well as pT703-RHAMM levels (Figure S10A)	RHAMM	S10A
158	In MCF10A cells, AURKA abundance and activity determined total RHAMM as well as pT703-RHAMM levels (Figure S10A)	RHAMM	S10A
159	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	AURKA	S11A
160	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	TPX2	S11A
161	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	HMMR	S11A
162	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and growth arrest of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)	BRCA1	S11A
163	According to the model and as stated above, analysis of public gene expression datasets suggests that the rs299290 risk allele is associated with HMMR germline over-expression (Table S3)	HMMR	rs299290
164	As the potential splicing alteration by rs299284 might be tissue specific and RHAMM-R92 was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of RHAMM function and/or expression level according to the depicted model.	RHAMM	rs299284
165	As the potential splicing alteration by rs299284 might be tissue specific and RHAMM-R92 was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of RHAMM function and/or expression level according to the depicted model.	RHAMM	rs299284
166	As the potential splicing alteration by rs299284 might be tissue specific and RHAMM-R92 was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of RHAMM function and/or expression level according to the depicted model.	RHAMM	R92
167	As the potential splicing alteration by rs299284 might be tissue specific and RHAMM-R92 was used in the over-expression assays, further work may be warranted to define the causal mutation(s) and the alteration of RHAMM function and/or expression level according to the depicted model.	RHAMM	R92
168	In preparation for mitotic spindle assembly, AURKA promotes centrosome-dependent microtubule assembly by suppressing BRCA1-dependent ubiquitination, which involves BRCA1 phosphorylation at S308	AURKA	S308
169	In preparation for mitotic spindle assembly, AURKA promotes centrosome-dependent microtubule assembly by suppressing BRCA1-dependent ubiquitination, which involves BRCA1 phosphorylation at S308	BRCA1	S308
170	In preparation for mitotic spindle assembly, AURKA promotes centrosome-dependent microtubule assembly by suppressing BRCA1-dependent ubiquitination, which involves BRCA1 phosphorylation at S308	BRCA1	S308
171	Accordingly, BRCA1 depletion increases the clonogenic potential of mammary epithelia, while a BRCA1 S308A mutant alters embryonic stem cell differentiation	BRCA1	S308A
172	Accordingly, BRCA1 depletion increases the clonogenic potential of mammary epithelia, while a BRCA1 S308A mutant alters embryonic stem cell differentiation	BRCA1	S308A
173	In order to reconstitute HCC1937 cells with wild-type BRCA1, the corresponding full-length open-reading frame was cloned into a retroviral vector S11N and transduced	BRCA1	S11N
174	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; FIS 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"	FIS	C1287/A8874
175	The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon.	BRCA1	185delAG
176	The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon.	BRCA1	c.68_69delAG
177	Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk.	STK15	F31I
